#### THE SENATE TWENTY-FIFTH LEGISLATURE, 2009 STATE OF HAWAII

S.B. NO. 448

JAN 2 3 2009

#### A BILL FOR AN ACT

RELATING TO MEDICAL CANNABIS.

#### BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

SECTION 1. The legislature finds that the State's medical marijuana program, enacted into law in 2000, is a public health program conceived out of concern for the health and welfare of the seriously ill. Registration for the program is currently administered by the narcotics enforcement division of the department of public safety.

7 Many patients, however, are intimidated by the prospect of 8 dealing with a narcotics enforcement agency, and do not apply 9 for certification. Therefore, they do not benefit from the 10 protection from arrest or the threat of arrest by state or 11 county authorities that is offered to those who are certified by 12 the State under this program.

Furthermore, the program's current placement in the narcotics enforcement division is in part responsible for the reluctance of many physicians to certify patients. These physicians are concerned that their written certifications will be reviewed by the same entity that monitors physicians on

1 issues of over-prescribing, "doctor shopping," and similar
2 issues.

In June 2008 the department of public safety violated patients' privacy by mistakenly releasing private patient information to a reporter for the Hawaii Tribune-Herald. The list included the name of each of the four thousand two hundred patients, the location of their cannabis plants, license information, and the names of their physicians.

9 Since the mission of the department of health is "to 10 protect and improve the health and environment for all people in 11 Hawaii, the department is experienced in dealing with private 12 health records, and the use of medical cannabis is properly 13 regarded as a health issue, not simply as an exception to the 14 State's laws on controlled substances, the legislature finds 15 that the State's medical marijuana program would be more 16 properly administered by the department of health rather than by 17 the department of public safety.

18 Further, the department of health is already part of the 19 medical use of medical marijuana program as existing law confers 20 upon the department of health the power to add new debilitating 21 conditions to those which would permit medical cannabis use.

1	The purpose of this Act is to transfer administration of			
2	the State's program for the medical use of marijuana from the			
3	department of public safety to the department of health, and to			
4	amend the medical use of marijuana law to replace the term,			
5	"marijuana" with "cannabis". In addition, this Act establishes			
6	the medical cannabis advisory board that shall identify			
7	requirements for the licensure of producers and cannabis			
8	production facilities and set forth procedures to obtain			
9	licenses and develop a distribution system for medical cannabis.			
10	SECTION 2. Chapter 329, Hawaii Revised Statutes, is			
11	amended by adding two new sections to part IX to be			
12	appropriately designated and to read as follows:			
13	" <u>§329-</u> <u>Medical cannabis advisory board; establishment.</u>			
13 14	"§329- Medical cannabis advisory board; establishment. (a) There is established within the department of health the			
14	(a) There is established within the department of health the			
14 15	(a) There is established within the department of health the medical cannabis advisory board.			
14 15 16	<ul> <li>(a) There is established within the department of health the medical cannabis advisory board.</li> <li>(b) The advisory board shall consist of eleven members,</li> </ul>			
14 15 16 17	<ul> <li>(a) There is established within the department of health the medical cannabis advisory board.</li> <li>(b) The advisory board shall consist of eleven members, three of which shall be qualified medical cannabis patients,</li> </ul>			
14 15 16 17 18	<ul> <li>(a) There is established within the department of health the medical cannabis advisory board.         <ul> <li>(b) The advisory board shall consist of eleven members,</li> <li>three of which shall be qualified medical cannabis patients,</li> <li>seven of which shall be practitioners representing the fields of</li> </ul> </li> </ul>			
14 15 16 17 18 19	<ul> <li>(a) There is established within the department of health the medical cannabis advisory board.         <ul> <li>(b) The advisory board shall consist of eleven members,</li> <li>three of which shall be qualified medical cannabis patients,</li> <li>seven of which shall be practitioners representing the fields of</li> <li>neurology, pain management, medical oncology, psychiatry,</li> </ul> </li> </ul>			
14 15 16 17 18 19 20	<ul> <li>(a) There is established within the department of health the medical cannabis advisory board.         <ul> <li>(b) The advisory board shall consist of eleven members,</li> <li>three of which shall be qualified medical cannabis patients,</li> <li>seven of which shall be practitioners representing the fields of</li> <li>neurology, pain management, medical oncology, psychiatry,</li> <li>infectious disease, family medicine, and gynecology. The</li> </ul> </li> </ul>			
14 15 16 17 18 19 20 21	<ul> <li>(a) There is established within the department of health the medical cannabis advisory board.         <ul> <li>(b) The advisory board shall consist of eleven members,</li> <li>three of which shall be qualified medical cannabis patients,</li> <li>seven of which shall be practitioners representing the fields of neurology, pain management, medical oncology, psychiatry,</li> <li>infectious disease, family medicine, and gynecology. The practitioners shall be nationally board-certified in their area</li> </ul> </li> </ul>			

1	cannabis.	The chairperson of the board and the members shall be
2	appointed	by the director of health or the director's designee.
3	<u>(c)</u>	The advisory board shall:
4	(1)	Review and recommend to the department for approval
5		additional debilitating medical conditions that would
6		benefit from the medical use of cannabis;
7	(2)	Issue recommendations concerning rules to be adopted
8		for the issuance of registry identification cards,
9		including the manner in which the department shall
10		consider applications for registry identification
11		cards and for the renewal of identification cards for
12		qualified patients and primary caregivers;
13	(3)	Identify requirements for the licensure of producers
14		and cannabis production facilities and set forth
15		procedures to obtain licenses;
16	(4)	Develop a distribution system for medical cannabis
17		that provides for:
18		(A) Cannabis production facilities within the State
19		of Hawaii housed on secured grounds and operated
20		by licensed producers; and
21		(B) Distribution of medical cannabis to qualified
22		patients or their primary caregivers to take



Page 4

1			place at locations that are designated by the
2			department and that are not within three hundred
3			feet of any school, church or daycare center;
4	(5)	Dete	rmine additional duties and responsibilities of
5		the	advisory board; and
6	(6)	Subm	it annual reports to the legislature no later than
7		twen	ty days prior to the convening of each regular
8		sess	ion that shall include:
9		<u>(A)</u>	Any issues and concerns relating to the
10			implementation of the medical cannabis program;
11		<u>(B)</u>	The total number of licensed producers,
12			qualifying patients, and primary caregivers that
13			have utilized the program; provided that no
14		,	personal, identifying information of producers,
15			qualifying patients or primary caregivers is
16			included;
17		<u>(C)</u>	An evaluation of the effectiveness of the program
18			in providing medical cannabis to individuals
19			suffering from debilitating illnesses; and
20		<u>(D)</u>	Any recommendations, including proposed
21			legislation, to improve the provisions of the
22			medical cannabis program.

1	(d) Members of the medical cannabis advisory board shall
2	serve without compensation and shall not receive reimbursements
3	for expenses.
4	<b>§329-</b> Protections afforded to a licensed producer. (a)
5	A licensed producer shall not be subject to arrest, prosecution,
6	or penalty, in any manner, for the production, possession,
7	distribution, or dispensing of cannabis; provided that the
8	licensed producer strictly complied with the requirements of
9	this part.
10	(b) A licensed producer may assert the medical use of
11	cannabis as an affirmative defense to any prosecution involving
12	cannabis under this part or chapter 712; provided that the
13	licensed producer strictly complied with the requirements of
14	this part.
15	(c) Any licensed producer not complying with the permitted
16	scope of the medical use of cannabis shall not be afforded the
17	protections against searches and seizures pertaining to the
18	misapplication of the medical use of cannabis."
19	SECTION 3. Section 329-14, Hawaii Revised Statutes, is
20	amended to read as follows:
21	"§329-14 Schedule I. (a) The controlled substances
22	listed in this section are included in schedule I.
	2009-0503 SB SMA.doc

Page 6

1	(b)	Any of the following opiates, including their isomers,
2	esters, e	ethers, salts, and salts of isomers, esters, and ethers,
3	unless sp	pecifically excepted, whenever the existence of these
4	isomers,	esters, ethers, and salts is possible within the
5	specific	chemical designation:
6	(1)	Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-
7		<pre>phenethyl)-4-piperidinyl]-N-phenylacetamide);</pre>
8	(2)	Acetylmethadol;
9	(3)	Allylprodine;
10	(4)	Alphacetylmethadol (except levo-alphacetylmethadol,
11		levomethadyl acetate, or LAAM);
12	(5)	Alphameprodine;
13	(6)	Alphamethadol;
14	(7)	Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-
15		phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-
16		2-phenylethyl)-4-(N-propanilido) piperidine);
17	(8)	Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
18		thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
19	(9)	Benzethidine;
20	(10)	Betacetylmethadol;
21	(11)	Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
22		piperidinyl]-N-phenylpropanamide;

1	(12)	Beta-hydroxy-3-methylfentanyl (N-[1-(2- hydroxy-2-
2		phenethyl)-3-methyl-4-piperidinyl]-N-
3		phenylpropanamide);
4	(13)	Betameprodine;
5	(14)	Betamethadol;
6	(15)	Betaprodine;
7	(16)	Clonitazene;
8	(17)	Dextromoramide;
9	(18)	Diampromide;
10	(19)	Diethylthiambutene;
11	(20)	Difenoxin;
12	(21)	Dimenoxadol;
13	(22)	Dimepheptanol;
14	(23)	Dimethylthiambutene;
15	(24)	Dioxaphetyl butyrate;
16	(25)	Dipipanone;
17	(26)	Ethylmethylthiambutene;
18	(27)	Etonitazene;
19	(28)	Etoxeridine;
20	(29)	Furethidine;
21	(30)	Hydroxypethidine;
22	(31)	Ketobemidone;

1	(32)	Levomoramide;
2	(33)	Levophenacylmorphan;
3	(34)	3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-
4		<pre>piperidyl]-N-phenylpropanamide);</pre>
5	(35)	3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-
6		4-piperidinyl]-N-phenylpropanamide);
7	(36)	Morpheridine;
8	(37)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
9	(38)	Noracymethadol;
10	(39)	Norlevorphanol;
11	(40)	Normethadone;
12	(41)	Norpipanone;
13	(42)	Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-
14		phenethyl)-4-piperidinyl] propanamide;
15	(43)	PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine;
16	(44)	Phenadoxone;
17	(45)	Phenampromide;
18	(46)	Phenomorphan;
19	(47)	Phenoperidine;
20	(48)	Piritramide;
21	(49)	Proheptazine;
22	(50)	Properidine;
		SB SMA.doc ,



## S.B. NO. 418

10

1	(51)	Propiram;
2	(52)	Racemoramide;
3	(53)	Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-
4		<pre>piperidinyl]-propanamide);</pre>
5	(54)	Tilidine;
6	(55)	Trimeperidine;
7	(56)	N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
8		(benzylfentanyl), its optical isomers, salts, and
9		salts of isomers; and
10	(57)	N-[1-(2-thienyl)methyl-4-piperidyl]-N-
11		phenylpropanamide (thenylfentanyl), its optical
12		isomers, salts, and salts of isomers.
13	(c)	Any of the following opium derivatives, their salts,
14	isomers,	and salts of isomers, unless specifically excepted,
15	whenever	the existence of these salts, isomers, and salts of
16	isomers i	s possible within the specific chemical designation:
17	(1)	Acetorphine;
18	(2)	Acetyldihydrocodeine;
19	(3)	Benzylmorphine;
20	(4)	Codeine methylbromide;
21	(5)	Codeine-N-Oxide;
22	(6)	Cyprenorphine;
	2009-0503	SB SMA.doc

## S.B. NO. 418

11

1	(7)	Desomorphine;
2	(8)	Dihydromorphine;
3	(9)	Drotebanol;
4	(10)	Etorphine;
5	, (11)	Heroin;
6	(12)	Hydromorphinol;
. 7	(13)	Methyldesorphine;
8	(14)	Methyldihydromorphine;
9	(15)	Morphine methylbromide;
10	(16)	Morphine methylsulfonate;
11	(17)	Morphine-N-Oxide;
12	(18)	Myrophine;
13	(19)	Nicocodeine;
14	(20)	Nicomorphine;
15	(21)	Normorphine;
16	(22)	Phoclodine;
17	(23)	Thebacon.
18	(d)	Any material, compound, mixture, or preparation that
19	contains	any quantity of the following hallucinogenic
20	substance	s, their salts, isomers, and salts of isomers, unless
21	specifica	lly excepted, whenever the existence of these salts,

12

•		
1	isomers,	and salts of isomers is possible within the specific
2	chemical	designation:
3	(1)	Alpha-ethyltryptamine (AET);
4	(2)	2,5-dimethoxy-4-ethylamphetamine (DOET);
5	(3)	2,5-dimethoxyamphetamine (2,5-DMA);
6	(4)	3,4-methylenedioxy amphetamine;
7	(5)	3,4-methylenedioxymethamphetamine (MDMA);
8	(6)	N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-
9		MDA);
10	(7)	3,4-methylenedioxy-N-ethylamphetamine (MDE);
11	(8)	5-methoxy-3,4-methylenedioxy-amphetamine;
12	(9)	4-bromo-2,5-dimethoxy-amphetamine(4-bromo-2,5-DMA);
13	(10)	4-Bromo-2,5-dimethoxyphenethylamine (Nexus);
14	(11)	3,4,5-trimethoxy amphetamine;
15	(12)	Bufotenine;
16	(13)	4-methoxyamphetamine (PMA);
17	(14)	Diethyltryptamine;
18	(15)	Dimethyltryptamine;
19	(16)	4-methyl-2,5-dimethoxy-amphetamine;
20	(17)	Gamma hydroxybutyrate (GHB) (some other names include
21		gamma hydroxybutyric acid; 4-hydroxybutyrate;

Page 13

13

1		4-hydroxybutanoic acid; sodium oxybate; sodium
2		oxybutyrate);
3	(18)	Ibogaine;
4	(19)	Lysergic acid diethylamide;
5	(20)	Marijuana;
6	(21)	Parahexyl;
7	(22)	Mescaline;
8	(23)	Peyote;
9	(24)	N-ethyl-3-piperidyl benzilate;
10	(25)	N-methyl-3-piperidyl benzilate;
11	(26)	Psilocybin;
12	(27)	Psilocyn;
13	(28)	1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy);
14	(29)	Tetrahydrocannabinols;
15	(30)	Ethylamine analog of phencyclidine (PCE);
16	(31)	Pyrrolidine analog of phencyclidine (PCPy, PHP);
17	(32)	Thiophene analog of phencyclidine (TPCP; TCP);
18	(33)	Gamma-butyrolactone, including butyrolactone;
19		butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone
20		dihydro; dihydro-2(3H)-furanone; tetrahydro-2-
21		<pre>furanone; 1,2-butanolide; 1,4-butanolide;</pre>
22		4-butanolide; gamma-hydroxybutyric acid lactone;



14

1		3-hydroxybutyric acid lactone and 4-hydroxybutanoic
2		acid lactone with Chemical Abstract Service number
3		96-48-0 when any such substance is intended for human
4		ingestion;
5	(34)	1,4 butanediol, including butanediol; butane-1,4-diol;
6		1,4- butylenes glycol; butylene glycol; 1,4-
7		dihydroxybutane; 1,4- tetramethylene glycol;
8		tetramethylene glycol; tetramethylene 1,4- diol with
9		Chemical Abstract Service number 110-63-4 when any
10		such substance is intended for human ingestion;
11	(35)	2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7),
12		its optical isomers, salts, and salts of isomers;
13	(36)	N-benzylpiperazine (BZP; 1-benzylpiperazine) its
14		optical isomers, salts, and salts of isomers;
15	(37)	1-(3-trifluoromethylphenyl)piperazine (TFMPP), its
16		optical isomers, salts, and salts of isomers;
17	(38)	Alpha-methyltryptamine (AMT), its isomers, salts, and
18		salts of isomers; and
19	(39)	5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its
20		isomers, salts, and salts of isomers.

1	(e) Depressants. Unless specifically excepted, the
2	schedule shall include any material, compound, mixture, or
3	preparation which contains any quantity of the substance:
4	(1) Mecloqualone; or
5	(2) Methaqualone.
6	(f) Stimulants. Unless specifically excepted or unless
7	listed in another schedule, any material, compound, mixture, or
8	preparation which contains any quantity of the following
9	substances having a stimulant effect on the central nervous
10	system, including its salts, isomers, and salts of isomers:
11	(1) Aminorex;
12	(2) Cathinone;
13	(3) Fenethylline;
14	(4) Methcathinone;
15	(5) N-ethylamphetamine;
16	(6) 4-methylaminorex;
17	(7) N,N-dimethylamphetamine.
18	(g) The enumeration of marijuana, tetrahydrocannabinols,
19	or chemical derivatives of tetrahydrocannabinol as Schedule I
20	controlled substances does not apply to the use or possession of
21	marijuana, tetrahydrocannabinols, or chemical derivatives of
22	tetrahydrocannabinol by qualified patients, primary care givers,
	2009-0503 SB SMA.doc 15

16

1	or licensed producers pursuant to part IX of chapter 329
2	regarding the medical use of cannabis."
3	SECTION 4. Chapter 329, part IX, Hawaii Revised Statutes,
4	is amended by amending its title to read as follows:
5	"[+]PART IX.[+] MEDICAL USE OF [MARIJUANA] <u>CANNABIS</u> "
6	SECTION 5. Section 329-121, Hawaii Revised Statutes, is
7	amended to read as follows:
8	"[+]§329-121[+] Definitions. As used in this part:
9	"Adequate supply" means an amount of [ <del>marijuana</del> ] <u>cannabis</u>
10	jointly possessed between the qualifying patient and the primary
11	caregiver that is not more than is reasonably necessary to
12	assure the uninterrupted availability of [marijuana] cannabis
13	for the purpose of alleviating the symptoms or effects of a
14	qualifying patient's debilitating medical condition; provided
15	that an "adequate supply" shall not exceed three mature
16	[ <del>marijuana</del> ] <u>cannabis</u> plants, four immature [ <del>marijuana</del> ] <u>cannabis</u>
17	plants, and one ounce of usable [marijuana] cannabis per each
18	mature plant.
19	"Department" means the department of health.
20	"Debilitating medical condition" means:

Page 17

17

1	(1)	Cancer, glaucoma, positive status for human
2		immunodeficiency virus, acquired immune deficiency
3		syndrome, or the treatment of these conditions;
4	(2)	A chronic or debilitating disease or medical condition
5		or its treatment that produces one or more of the
6		following:
7		(A) Cachexia or wasting syndrome;
8		(B) Severe pain;
9		(C) Severe nausea;
10		(D) Seizures, including those characteristic of
11		epilepsy; or
12		(E) Severe and persistent muscle spasms, including
13		those characteristic of multiple sclerosis or
14		Crohn's disease; or
15	(3)	Any other medical condition approved by the department
16		of health pursuant to administrative rules in response
17		to a request from a physician or potentially
18		qualifying patient.
19	[ <u>"Ma</u> :	rijuana"] <u>"Cannabis"</u> shall have the same meaning as
20	"marijuan	a" and "marijuana concentrate" as provided in sections
21	329–1 and	712-1240.

#### S.B. NO. 418

"Licensed producer" means any person or association of
 persons within the State of Hawaii that the department of health
 determines to be qualified to produce, possess, distribute, and
 dispense cannabis pursuant to this part and that is licensed by
 the department.

6 "Medical use" means the acquisition, possession, 7 cultivation, use, distribution, or transportation of [marijuana] 8 cannabis or paraphernalia relating to the administration of 9 [marijuana] cannabis to alleviate the symptoms or effects of a 10 qualifying patient's debilitating medical condition. For the 11 purposes of "medical use", the term distribution is limited to 12 the transfer of [marijuana] cannabis and paraphernalia from the 13 primary caregiver to the qualifying patient.

14 "Physician" means a person who is licensed under chapters 15 453 and 460, and is licensed with authority to prescribe drugs 16 and is registered under section 329-32. "Physician" does not 17 include physician's assistant as described in section 453-5.3.

18 "Primary caregiver" means a person, other than the 19 qualifying patient and the qualifying patient's physician, who 20 is eighteen years of age or older who has agreed to undertake 21 responsibility for managing the well-being of the qualifying 22 patient with respect to the medical use of [marijuana.]

#### S.B. NO. 418

<u>cannabis.</u> In the case of a minor or an adult lacking legal
 capacity, the primary caregiver shall be a parent, guardian, or
 person having legal custody.

4 "Qualifying patient" means a person who has been diagnosed 5 by a physician as having a debilitating medical condition. 6 ["Usable marijuana"] "Usable cannabis" means the dried 7 leaves and flowers of the plant Cannabis family Moraceae, and 8 any mixture [+]or[+] preparation thereof, that are appropriate 9 for the medical use of [marijuana.] cannabis. [<del>"Usable</del> 10 marijuana"] "Usable cannabis" does not include the seeds, 11 stalks, and roots of the plant.

12 "Written certification" means the qualifying patient's 13 medical records or a statement signed by a qualifying patient's 14 physician, stating that in the physician's professional opinion, 15 the qualifying patient has a debilitating medical condition and 16 the potential benefits of the medical use of [marijuana] 17 cannabis would likely outweigh the health risks for the 18 qualifying patient. The department of [public safety] health 19 may require, through its rulemaking authority, that all written 20 certifications comply with a designated form. "Written 21 certifications" are valid for only one year from the time of 22 signing."

#### S.B. NO. 418

1 Section 329-122, Hawaii Revised Statutes, is SECTION 6. 2 amended to read as follows: 3 "§329-122 Medical use of [marijuana;] cannabis; conditions 4 of use. (a) Notwithstanding any law to the contrary, the 5 medical use of [marijuana] cannabis by a qualifying patient 6 shall be permitted only if: 7 (1)The qualifying patient has been diagnosed by a 8 physician as having a debilitating medical condition; 9 (2)The qualifying patient's physician has certified in 10 writing that, in the physician's professional opinion, 11 the potential benefits of the medical use of 12 [marijuana] cannabis would likely outweigh the health 13 risks for the particular qualifying patient; and 14 The amount of [marijuana] cannabis does not exceed an (3) 15 adequate supply. 16 Subsection (a) shall not apply to a qualifying patient (b) 17 under the age of eighteen years, unless: 18 The qualifying patient's physician has explained the (1)19 potential risks and benefits of the medical use of 20 [marijuana] cannabis to the qualifying patient and to 21 a parent, quardian, or person having legal custody of 22 the qualifying patient; and

# S.B. NO. 418

21

1	(2)	A parent, guardian, or person having legal custody
2		consents in writing to:
3		(A) Allow the qualifying patient's medical use of
4		[marijuana;] cannabis;
5		(B) Serve as the qualifying patient's primary
6		caregiver; and
7		(C) Control the acquisition of the [marijuana,]
8		cannabis, the dosage, and the frequency of the
9		medical use of [marijuana] cannabis by the
10		qualifying patient.
11	(c)	The authorization for the medical use of [marijuana]
12	cannabis	in this section shall not apply to:
13	(1)	The medical use of [marijuana] cannabis that endangers
14	- -	the health or well-being of another person;
15	(2)	The medical use of [marijuana:] cannabis:
16		(A) In a school bus, public bus, or any moving
17		vehicle;
18		(B) In the workplace of one's employment;
19		(C) On any school grounds;
20		(D) At any public park, public beach, public
21		recreation center, recreation or youth center; or

### S.B. NO. 418

1	(E) [ <del>Other</del> ] <u>At any other</u> place open to the public;	
2	and	
3	(3) The use of [ <del>marijuana</del> ] <u>cannabis</u> by a qualifying	
4	patient, parent, or primary caregiver for purposes	
5	other than medical use permitted by this part."	
6	SECTION 7. Section 329-123, Hawaii Revised Statutes, is	
<b>7</b> ·	amended to read as follows:	
8	"[ <b>+</b> ]§ <b>329-123[+</b> ] <b>Registration requirements.</b> (a)	
9	Physicians who issue written certifications shall register the	
10	names, addresses, patient identification numbers, and other	
11	identifying information of the patients issued written	
12	certifications with the department of [public safety.] health.	
13	The department of health shall provide the department of public	
14	safety, on a weekly basis, a copy of the information provided by	
15	physicians.	
16	(b) Qualifying patients shall register with the department	
17	of [ <del>public safety.</del> ] <u>health.</u> Such registration shall be	
18	effective until the expiration of the certificate issued by the	
19	physician. Every qualifying patient shall provide sufficient	
20	identifying information to establish personal identity of the	
21	qualifying patient and the primary caregiver. Qualifying	
22	patients shall report changes in information within five working	
	2009-0503 SB SMA.doc	

## S.B. NO. 418

23

1	days. Every qualifying patient shall have only one primary		
2	caregiver at any given time. The department shall then issue to		
3	the qualifying patient a registration certificate, and may		
4	charge a reasonable fee not to exceed [ $\frac{25}{50}$ ] $\frac{50}{50}$ . The		
5	department of health shall provide the department of public		
6	safety, on a weekly basis, a copy of the information provided by		
7	qualifying patients.		
8	(c) Primary caregivers shall register with the department		
9	of [ <del>public safety.</del> ] <u>health.</u> Every primary caregiver shall be		
10	responsible for the care of only one qualifying patient at any		
11	given time. The department of health shall provide the		
12	department of public safety, on a weekly basis, a copy of the		
13	information provided by primary caregivers.		
14	(d) Upon an inquiry by a law enforcement agency, the		
15	department of [ <del>public-safety</del> ] <u>health</u> shall verify whether the		
16	particular qualifying patient or licensed producer has		
17	registered with the department and may provide reasonable access		
18	to the registry information for official law enforcement		
19	purposes."		
20	SECTION 8. Section 329-124, Hawaii Revised Statutes, is		
21	amended to read as follows:		

#### S.B. NO. 418

1 "[+]\$329-124[+] Insurance not applicable. This part shall 2 not be construed to require insurance coverage for the medical 3 use of [marijuana.] cannabis." 4 SECTION 9. Section 329-125, Hawaii Revised Statutes, is 5 amended to read as follows: 6 "[+]§329-125[+] Protections afforded to a qualifying 7 patient or primary caregiver. (a) A qualifying patient or the primary caregiver may assert the medical use of [marijuana] 8 9 cannabis as an affirmative defense to any prosecution involving 10 [marijuana] cannabis under this [+]part[+] or chapter 712; 11 provided that the qualifying patient or the primary caregiver 12 strictly complied with the requirements of this part. 13 Any qualifying patient or primary caregiver not (b) 14 complying with the permitted scope of the medical use of 15 [marijuana] cannabis shall not be afforded the protections 16 against searches and seizures pertaining to the misapplication 17 of the medical use of [marijuana.] cannabis. 18 No person shall be subject to arrest or prosecution (C) 19 for simply being in the presence or vicinity of the medical use 20 of [marijuana] cannabis as permitted under this part." 21 SECTION 10. Section 329-126, Hawaii Revised Statutes, is 22 amended to read as follows: 2009-0503 SB SMA.doc 

# S.B. NO. 418

25

1	"[ <del>[</del> ]	S329-126[+] Protections afforded to a treating
2	physician	. No physician shall be subject to arrest or
3	prosecuti	on, penalized in any manner, or denied any right or
4	privilege	for providing written certification for the medical
5	use of [m	arijuana] <u>cannabis</u> for a qualifying patient; provided
6	that:	
7	(1)	The physician has diagnosed the patient as having a
8		debilitating medical condition, as defined in section
9		329-121;
10	(2)	The physician has explained the potential risks and
11		benefits of the medical use of [marijuana,] cannabis,
12		as required under section 329-122;
13	(3)	The written certification is based upon the
14		physician's professional opinion after having
15		completed a full assessment of the patient's medical
16		history and current medical condition made in the
17		course of a bona fide physician-patient relationship;
18		and
19	(4)	The physician has complied with the registration
20		requirements of section 329-123."
21	SECT	ION 11. Section 329-127, Hawaii Revised Statutes, is
22	amended t	o read as follows:

#### S.B. NO. 418

1 "[+]\$329-127[+] Protection of [marijuana] cannabis and 2 other seized property. [Marijuana,] Cannabis, paraphernalia, or 3 other property seized from a qualifying patient or primary 4 caregiver in connection with a claimed medical use of 5 [marijuana] cannabis under this part shall be returned 6 immediately upon the determination by a court that the 7 qualifying patient or primary caregiver is entitled to the 8 protections of this part, as evidenced by a decision not to 9 prosecute, dismissal of charges, or an acquittal; provided that 10 law enforcement agencies seizing live plants as evidence shall 11 not be responsible for the care and maintenance of [such] the 12 plants." SECTION 12. Section 329-128, Hawaii Revised Statutes, is 13

13 SECTION 12. Section 329-128, Hawaii Revised Statutes, is 14 amended to read as follows:

15 "[+]§329-128[+] Fraudulent misrepresentation; penalty. 16 (a) Notwithstanding any law to the contrary, fraudulent 17 misrepresentation to a law enforcement official of any fact or 18 circumstance relating to the medical use of [marijuana] cannabis 19 to avoid arrest or prosecution under this part or chapter 712 20 shall be a petty misdemeanor and subject to a fine of \$500. 21 Notwithstanding any law to the contrary, fraudulent (b) misrepresentation to a law enforcement official of any fact or 22



#### S.B. NO. 418

circumstance relating to the issuance of a written certificate 1 by a physician not covered under section 329-126 for the medical 2 3 use of [marijuana] cannabis shall be a misdemeanor. This 4 penalty shall be in addition to any other penalties that may apply for the non-medical use of [marijuana.] cannabis. Nothing 5 6 in this section is intended to preclude the conviction of any person under section 710-1060 or for any other offense under 7 8 part V of chapter 710. 9 (c) If a licensed producer sells, distributes, dispenses 10 or transfers cannabis to a person not approved by the department 11 pursuant to this part or obtains or transports cannabis outside 12 the State of Hawaii in violation of federal law, the licensed producer shall be subject to arrest, prosecution, and civil or 13 14 criminal penalties pursuant to state law." 15 SECTION 13. This Act does not affect rights and duties that matured, penalties that were incurred, and proceedings that 16 17 were begun, before its effective date. SECTION 14. All appropriations, records, equipment, files, 18 supplies, contracts, books, papers, documents, maps, computer 19 20 software and data, authorizations and other property, both real and personal, heretofore made, used, acquired, or held by the 21

22 department of public safety in the exercise of the functions and



14

#### S.B. NO. 418

programs transferred by the Act shall be transferred to the 1 2 department of health when the functions or programs are 3 transferred.

SECTION 15. All rules or other documents executed or 4 5 entered into by or on behalf of the department of public safety 6 pursuant to the provisions of part IX of chapter 329, Hawaii 7 Revised Statutes, which are reenacted or made applicable to the 8 department of health by this Act, shall remain in full force and 9 effect until amended or repealed by the department of health pursuant to chapter 91, Hawaii Revised Statutes. 10

11 SECTION 16. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored. 12

13 SECTION 17. This Act shall take effect upon its approval.

INTRODUCED BY: And July (BR)



#### Report Title:

Medical Marijuana; Medical Cannabis; Department of Health; Dispensaries; Licensed Producer

#### Description:

2009-0503 SB SMA.doc

Amends the term "medical marijuana" to "medical cannabis"; transfers the administration of the program from the department of public safety to the department of health; authorizes a registration fee of \$50; establishes the medical cannabis advisory board; provides for the department of health to license producers to dispense medical cannabis.